more

GENFIT (GNFT)

(Delayed Data from NSDQ)

$3.41 USD

-0.18 (-5.01%)

Updated Apr 19, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	18.00%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.53%
S&P	500	11.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research Published on September 26,2023

After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

GNFTNegative Net Change

What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock

by Zacks Equity Research Published on April 14,2022

GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GNFTNegative Net Change

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on January 11,2022

The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

GNFTNegative Net Change

How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60%

by Zacks Equity Research Published on December 23,2021

The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

GNFTNegative Net Change

Intercept (ICPT) Posts New Positive Results on NASH Drug

by Zacks Equity Research Published on August 28,2020

Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.

biotechs

Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on August 11,2020

Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.

Intercept Slumps as the FDA Issues CRL to NASH Candidate

by Zacks Equity Research Published on June 30,2020

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

biotechs

Is Genfit (GNFT) Stock a Solid Choice Right Now

by Zacks Equity Research Published on June 10,2020

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GNFTNegative Net Change

Intercept Down on Postponement of AdCom Meet for NASH Drug

by Zacks.com Published on May 26,2020

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.